Literature DB >> 6206240

The development of human benign prostatic hyperplasia with age.

S J Berry, D S Coffey, P C Walsh, L L Ewing.   

Abstract

In this study we report the prevalence and growth rate of human benign prostatic hyperplasia with age by combining and analyzing data from 10 independent studies containing more than 1,000 prostates. The normal prostate reaches 20 plus or minus 6 gm. in men between 21 and 30 years old, and this weight remains essentially constant with increasing age unless benign prostatic hyperplasia develops. The prevalence of pathological benign prostatic hyperplasia is only 8 per cent at the fourth decade; however, 50 per cent of the male population has pathological benign prostatic hyperplasia when they are 51 to 60 years old. The average weight of a prostate that is recognized at autopsy to contain benign prostatic hyperplasia is 33 plus or minus 16 gm. Only 4 per cent of the prostates in men more than 70 years old reach sizes greater than 100 gm. An analysis of a logistic growth curve of benign prostatic hyperplasia lesions removed at prostatectomy indicates that the growth of benign prostatic hyperplasia is initiated probably before the patient is 30 years old. The early phase of benign prostatic hyperplasia growth (men between 31 and 50 years old) is characterized by a doubling time for the tumor weight of 4.5 years. In the mid phase of benign prostatic hyperplasia growth (men between 51 and 70 years old) the doubling time is 10 years, and increases to more than 100 years in patients beyond 70 years old.

Entities:  

Mesh:

Year:  1984        PMID: 6206240     DOI: 10.1016/s0022-5347(17)49698-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  455 in total

Review 1.  Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life.

Authors:  Donald MacDonald; Thomas A McNicholas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.

Authors:  J L Pool; R S Kirby
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 3.  The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data.

Authors:  Jaspreet S Sandhu; Alexis E Te
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

4.  Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats.

Authors:  Alexandre Fornari; Ernani Luis Rhoden; Cláudio G Zettler; Eduardo P Ribeiro; Claudia R Rhoden
Journal:  Int Urol Nephrol       Date:  2010-06-08       Impact factor: 2.370

5.  Incidence, predictors, and associated outcomes of prostatism after kidney transplantation.

Authors:  Frank P Hurst; Robert T Neff; Edward M Falta; Rahul M Jindal; Krista L Lentine; John S Swanson; Lawrence Y Agodoa; Kevin C Abbott
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 8.237

Review 6.  Predictive medicine in non-malignant urological disorders.

Authors:  Mariangela Mancini; Antonio Cisternino; Ivan Matteo Tavolini; Fabrizio Dal Moro; Pierfrancesco Bassi
Journal:  World J Urol       Date:  2003-12-20       Impact factor: 4.226

7.  Transurethral microwave treatment for benign prostatic hypertrophy: a randomised controlled clinical trial.

Authors:  A S Bdesha; C J Bunce; J P Kelleher; M E Snell; J Vukusic; R O Witherow
Journal:  BMJ       Date:  1993-05-15

Review 8.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 9.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

10.  Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.

Authors:  Reith R Sarkar; J Kellog Parsons; Alex K Bryant; Stephen T Ryan; Andrew K Kader; Rana R McKay; Anthony V D'Amico; Paul L Nguyen; Benjamin J Hulley; John P Einck; Arno J Mundt; Christopher J Kane; James D Murphy; Brent S Rose
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.